吡啶斯的明治疗重症肌无力的随机双盲安慰剂对照交叉试验
该随机双盲安慰剂对照交叉试验在抗乙酰胆碱受体抗体阳性重症肌无力患者中评估吡啶斯的明的疗效与成本效用。19例患者接受5天吡啶斯的明或安慰剂治疗,洗脱2天后交叉。吡啶斯的明在MGII评分上优于安慰剂(均差5.3,95%CI 1.9-8.7,p=0.004),并降低社会成本、改善质量调整生命年。
要点
- 吡啶斯的明改善MGII评分,均差5.3(95%CI 1.9-8.7,p=0.004)。
- QMG、MG-ADL和MG-QoL15r评分均显示吡啶斯的明优于安慰剂。
- 吡啶斯的明降低年社会成本并改善QALYs。
核心结论
- 在长期使用吡啶斯的明的AChR抗体阳性重症肌无力患者中,吡啶斯的明在所有疗效指标上均优于安慰剂,并大幅降低社会成本。
研究设计与样本
- 随机、双盲、安慰剂对照交叉试验,在荷兰莱顿大学医学中心开展,共纳入19例患者(中位年龄59岁,58%女性)。
- 患者随机接受5天吡啶斯的明或安慰剂治疗,洗脱2天后交叉,吡啶斯的明剂量与入组前方案一致。
主要发现
- MGII评分均差5.3(95%CI 1.9-8.7,p=0.004),QMG评分均差1.4(95%CI 0.5-2.3),MG-ADL评分均差1.2(95%CI 0.5-1.8),MG-QoL15r评分均差2.0(95%CI 0.03-3.91)。
- 事后成本效用分析显示吡啶斯的明组年社会成本降低€6,565(95%CI €328-€15,945),年QALYs改善0.106(95%CI 0.019-0.210)。
临床怎么用
- 对于抗AChR抗体阳性、标准治疗稳定且正在使用吡啶斯的明的成人眼肌型或全身型重症肌无力患者,吡啶斯的明可改善症状。
局限性
- 样本量小(19例),交叉治疗期短(5天),成本效用分析为事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Pyridostigmine, an acetylcholinesterase inhibitor, is a symptomatic drug approved for the treatment of myasthenia gravis (MG), but no randomized controlled trials substantiate its widespread use. We aimed to assess the efficacy and cost utility of pyridostigmine in patients with anti-acetylcholine receptor-positive MG (AChR MG). METHODS: A randomized, double-blind, placebo-controlled crossover trial was conducted at Leiden University Medical Center, a tertiary center for the treatment of MG in the Netherlands. Main eligibility criteria were current use of pyridostigmine and a stable dose of other MG treatments. Participants were assigned to a sequence of 2 treatment periods for 5 days separated by a 2-day washout, in which patients either first received placebo and then pyridostigmine, or vice versa. Pyridostigmine dosing matched each participant's prestudy regimen. The primary outcome was change in the Myasthenia Gravis Impairment Index (MGII) score. Secondary efficacy outcome measures included the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, the Quantitative Myasthenia Gravis (QMG) score, and the revised 15-item Myasthenia Gravis Quality of Life (MG-QOL15r) questionnaire. For the post hoc cost-utility analysis, a mathematical model was developed to translate the observed study results into long-term annual effect on societal costs and quality-adjusted life years (QALYs). RESULTS: A total of 19 patients (median age 59 years, 58% female) were recruited between March 23, 2023, and February 21, 2024. The estimated mean difference in the MGII score between pyridostigmine and placebo interventions was 5.3 (95% CI 1.9-8.7, p = 0.004). Secondary efficacy outcome measures showed estimated mean differences of 1.4 (95% CI 0.5-2.3) for the QMG score, 1.2 (95% CI 0.5-1.8) for the MG-ADL score, and 2.0 (95% CI 0.03-3.91) for the MG-QoL15r score. The post hoc cost-utility analysis showed lower annual societal costs (€6,565, 95% CI €328-€15,945) and annual improved QALYs (0.106, 95% CI 0.019-0.210) for patients using pyridostigmine. DISCUSSION: This trial showed that, in patients with AChR MG chronically treated with pyridostigmine, pyridostigmine demonstrated benefit over placebo across all efficacy outcome measures and substantially reduced societal costs. TRIAL REGISTRATION INFORMATION: The trial was registered at EudraCT (2021-004110-20, registration date: July 12, 2022) and ClinicalTrials.gov (NCT05919407, registration date: June 16, 2023). First patient enrolled: March 23, 2023. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that, in adults with AChR ab-positive ocular or generalized MG on stable standard-of-care therapy and currently using pyridostigmine, pyridostigmine improves MG symptoms compared with placebo.
引用
- Remijn-Nelissen L, Bakker WR, van den Hout WB, et al. Efficacy of Pyridostigmine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial. Neurology. 2026. PMID: 41945881. doi:10.1212/WNL.0000000000214865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。